ReviewJournal of clinical hypertension (Greenwich, Conn.)2004
Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 52 citations in OpenAlex.
- LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2016Trial
- Sartans and Bisartans: Expanding Therapeutic Horizons Through Broad Receptor Interactions and Repurposing Potential.International journal of molecular sciences · 2026Review
- ACE inhibitor-induced isolated intestinal angioedema mimicking functional bowel disorder: a case report.BMC gastroenterology · 2026Article
- Late-Onset Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in a General Practitioner's Practice: A Case Report.Reports (MDPI) · 2026Article
- Cumulative blood pressure exposure and cognition: the potential mediating role of brain volume.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Choosing the right antihypertensive drug to avoid intradialytic hypotension.Clinical kidney journal · 2025Article
- High-Throughput Screening for Prescribing Cascades Among Real-World Angiotensin-II Receptor Blockers (ARBs) Initiators.Pharmacotherapy · 2025Article
- The Hemoglobin, Albumin, Lymphocyte, and Platelet Score as a Prognostic Indicator for Dogs with Congestive Heart Failure Secondary to Myxomatous Mitral Valve Disease.Veterinary sciences · 2025Article
- Variability in Response to Valsartan and Its Relationship WithHealth science reports · 2025Article
- Kidney Toxicity of Drugs for the Heart: An Updated Perspective.Metabolites · 2025Review
- High-Throughput Screening for Prescribing Cascades Among Real-World Angiotensin-II Receptor Blockers (ARBs) Initiators.medRxiv : the preprint server for health sciences · 2025Article
- High-Throughput Screening for Prescribing Cascades Among Real-World Angiotensin-Converting Enzyme Inhibitor Initiators.Pharmacoepidemiology and drug safety · 2025Article
- Exploring disulfiram mechanisms in renal fibrosis: insights from biological data and computational approaches.Frontiers in pharmacology · 2025Article
- Antihypertensive Drug Treatment and the Risk for Intrahemodialysis Hypotension.Clinical journal of the American Society of Nephrology : CJASN · 2024Article
- Stevens-Johnson Syndrome From Combined Allopurinol and Angiotensin-Converting Enzyme Inhibitors: A Narrative Review.Cureus · 2024Review
- Evaluation of hypertension in systemic sclerosis and systemic lupus erythematosus overlap.Journal of scleroderma and related disorders · 2023Review
- Evaluation of the multifunctional dipeptidyl-peptidase IV and angiotensin converting enzyme inhibitory properties of a casein hydrolysate using cell-free and cell-based assays.Frontiers in nutrition · 2023Article
- Preparation, Characterization and In Vitro Stability of a Novel ACE-Inhibitory Peptide from Soybean Protein.Foods (Basel, Switzerland) · 2022Article
- Enalapril-induced angioedema: A forgotten adverse event.Clinical case reports · 2022Article
- An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin-converting enzyme (ACE) inhibitors are increasingly recognized as having an important role in the treatment of hypertension and/or end-organ disease. The sheer number of ACE inhibitors in the United States--now numbering 10 different chemical entities--has created a sense of comfort with these compounds, which is particularly evident when these compounds are used in the patient with essential hypertension; conversely, when comorbid conditions are present in the ACE inhibitor-treated patient, circumstances change and physician vigilance becomes more of a necessity. ACE inhibitor therapy in patients with either cardiac and/or renal disease is as much an art as it is a science, and even in the most skilled hands can prove a challenging undertaking. This review discusses the physiologic and non-physiologic basis for side effects with ACE inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.